Home » Stocks » Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. (AYLA)

Stock Price: $12.71 USD 0.07 (0.55%)
Updated Sep 22, 2020 12:37 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 162.41M
Revenue (ttm) 3.26M
Net Income (ttm) n/a
Shares Out 12.78M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 22, 2020
Last Price $12.71
Previous Close $12.64
Change ($) 0.07
Change (%) 0.55%
Day's Open 12.53
Day's Range 12.60 - 13.21
Day's Volume 2,538
52-Week Range 8.62 - 16.50

More Stats

Market Cap 162.41M
Enterprise Value 104.97M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.78M
Float 3.00M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1,983
Short Ratio 3.45
Short % of Float 0.28%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 49.77
PB Ratio 3.45
Revenue 3.26M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 57.44M
Net Cash / Share 4.49
Gross Margin 32.15%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -46.93%
ROE -91.70%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(66.18% upside)
Current: $12.71
Target: 21.12
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit1.05-
Operating Income-17.71-9.04
Net Income-17.79-8.87
Shares Outstanding4.984.94
Operating Cash Flow-14.95-6.37
Capital Expenditures-1.33-0.22
Free Cash Flow-16.28-6.59
Cash & Equivalents16.8126.26
Net Cash / Debt16.8126.26
Book Value-38.92-21.86
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ayala Pharmaceuticals, Inc.
Country Israel
Employees 31
CEO Roni Mamluk

Stock Information

Ticker Symbol AYLA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AYLA
IPO Date May 8, 2020


Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.